| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2012-06-15 | PankoMab™ | ovarian cancer | 2 | Glycotope (Germany) | Cancer - Oncology |
| 2012-06-15 | KBSA301 | severe pneumonia caused by Staphylococcus aureus (S. aureus) | 1-2 | Kenta Biotech (Switzerland) | Infectious diseases |
| 2012-06-14 | Mesupron® (upamostat) | HER2-receptor negative metastatic breast cancer | 2 | Wilex (Germany) | Cancer - Oncology |
| 2012-06-12 | Three-Month Formulation of Invega® Sustenna® (paliperidone palmitate) | schizophrenia |
3 | Alkermes (USA - Ireland) Janssen Research & Development (J&J - USA) | CNS diseases - Mental diseases |
| 2012-06-11 | Gilenya® (fingolimod) | relapsing-remitting multiple sclerosis |
3 | Novartis (Switzerland) | Autoimmune diseases - Neurodegenerative diseases |
| 2012-06-11 | Victoza® (liraglutide) | type 2 diabetes | observational study | Novo Nordisk (Denmark) | Metabolic diseases |
| 2012-06-11 | LY2605541 | type 1 and 2 diabetes | 2 | Boehringer Ingelheim (Germany) - Eli Lilly (USA) | Metabolic diseases |
| 2012-06-09 | albiglutide | type 2 diabetes | 3 | GSK (UK) | Metabolic diseases |
| 2012-06-09 | linagliptin (Tradjenta® in the US and Trajenta® in Europe) | type 2 diabetes | 3 | Boehringer Ingelheim (Germany) - Eli Lilly (USA) | Metabolic diseases |
| 2012-06-09 | empagliflozin (BI 10773) | type 2 diabetes | 2 | Boehringer Ingelheim (Germany) - Eli Lilly (USA) | Metabolic diseases |
| 2012-06-09 | insulin degludec | type 2 diabetes | 3a | Novo Nordisk (Denmark) | Metabolic diseases |
| 2012-06-09 | Bydureon® (exenatide) | type 2 diabetes |
Alkermes (USA - Ireland) Amylin Pharmaceuticals (USA) | Metabolic diseases | |
| 2012-06-09 | Bydureon™ (exenatide) | type 2 diabetes |
Alkermes (USA - Ireland) Amylin Pharmaceuticals (USA) | Metabolic diseases | |
| 2012-06-08 | FSH-GEX™ (glycooptimized follicle-stimulating hormone) | in vitro fertilisation FSH treatment of female infertility |
2 | Glycotope (Germany) | Gynecology - Women's health |
| 2012-06-06 | RoACTEMRA®/ACTEMRA® outside Europe (tocilizumab) | rheumatoid arthritis | 4 | Roche (Switzerland) Chugai (Japan) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2012-06-06 | ACZ885 (canakinumab) | systemic juvenile idiopathic arthritis (SJIA) |
3 | Novartis (Switzerland) | Autoimmune diseases - Rare diseases |
| 2012-06-06 | ACZ885 (canakinumab) | TNF Receptor-Associated Syndrome (TRAPS) |
2 | Novartis (Switzerland) | Autoimmune diseases - Rare diseases |
| 2012-06-06 | Atu027 | advanced solid tumours including neuroendocrine cancers and breast cancers |
1 | Silence Therapeutics (UK) | Cancer - Oncology |
| 2012-06-06 | abediterol | chronic obstructive pulmonary disease (COPD) | 2 | Almirall (Spain) | Respiratory diseases |
| 2012-06-06 | catumaxomab (Removab®) | malignant ascites due to epithelial cancer |
3b | Fresenius Biotech (Germany) | Cancer - Oncology |
